Ironwood is harvesting a manufactured net-price recovery in LINZESS, the constipation franchise it splits with AbbVie, and using that cash to keep a delayed rare-disease bet alive after regulators refused to file the first Phase 3 package. The investment debate is whether this year is a genuine reset of franchise economics or a last clean cash cycle before Medicare price setting and licensed generic entry shrink the annuity. Collaboration economics, not a diversified pipeline, still set the value of the equity. The company is no longer trying to look like a growth commercial organization. It is trying to look like a high-conversion cash engine that can finish one confirmatory trial before the franchise ages out.
In January the company and AbbVie cut the LINZESS list price by about half, a move designed to stop Inflation Reduction Act inflationary rebates from confiscating net realization. The mechanism worked in the reported quarter. United States LINZESS net sales reached $282.3 million. That print sat 14% above the year-ago period as commercial margin expanded. Ironwood booked $110 million of collaboration revenue from its half of brand profit. Management then lifted full-year LINZESS sales guidance, treating the rebound as more than a one-quarter reserve artifact. Shareholders should still separate durable net price from the favorable timing of rebate reserves that the company itself flags. Demand grew only in the mid-single digits. Price, not a new wave of patients, did most of the work.
The tension is concentration and time. Substantially all revenue still comes from one product, one partner, and one country. Cash fell to $79.1 million after the firm retired $200 million of convertible notes in June. A $385 million revolver remains the residual leverage. Apraglutide, the once-weekly glucagon-like peptide analog bought with VectivBio, is back in a confirmatory Phase III trial called STARS-2 because delivered dose and exposure in the original STARS study ran below plan. That setback crushed the equity in the spring of last year and opened a Goldman Sachs review that has yet to produce a transaction. The review is still the unpriced call option sitting next to the cash-harvest story.
What decides the next several quarters is whether LINZESS net price holds as demand stays only modest, whether STARS-2 enrolls a clean confirmatory cohort, and whether free cash after trial spend actually retires revolver principal. The market already prices a wasting annuity. Enterprise value near $1.01 billion sits against guided adjusted EBITDA above $310 million. That multiple is either cheap insurance on a still-live rare-disease option or a correct discount on a franchise whose best year is the one already in progress.